GW Pharmaceuticals PLC Holding(s) in Company (5065C)
June 28 2016 - 6:14AM
UK Regulatory
TIDMGWP
RNS Number : 5065C
GW Pharmaceuticals PLC
28 June 2016
For filings with the FCA
include the annex
For filings with issuer exclude
the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
-----------------------------------------------------------------------------------------------------
1. Identity of the issuer or GW PHARMACEUTICALS PLC
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
--------------------------------------------------------------- ------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
-----------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
------------------------------------------------------------------ ---------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------ ---------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------ ---------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------ ---------------------------------
Other (please
specify):
--------------------------------------------------------- ------- ---------------------------------
3. Full name of person(s) The Bank of New York Mellon
subject to the Corporation
notification obligation:
(iii)
----------------------------------------------------------- ----------------------------------------
4. Full name of shareholder(s) The Bank of New York Mellon;
(if different from 3.):(iv) The Dreyfus Corporation; The
Boston Company Asset Management
LLC; BNY Mellon, National
Association; Pershing LLC.
----------------------------------------------------------- ----------------------------------------
5. Date of the transaction 24 June 2016
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- ----------------------------------------
6. Date on which issuer 27 June 2016
notified:
----------------------------------------------------------- ----------------------------------------
7. Threshold(s) that is/are Crossing above 5%
crossed or
reached: (vi, vii)
----------------------------------------------------------- ----------------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- ----------------------------------- ------------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights (x)
Shares Voting
Rights
------------- ---------------- ----------------- -------------- ----------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ------------ ------------- -------------- --------- ------------ ------------ -----------
Common Stock 12,149 12,149 12,149 N/A 12,149 N/A 0.0046%
GB0030544687
ADR 1,094,236 13,130,829 1,095,460 N/A 13,145,517 N/A 4.9995%
---------------- ----------------- -------------- --------- ------------ ------------ -----------
US36197T1034
------------- ------------ ------------- ------------ ------- ------------ -------- ---------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- -------------- --------------------------------- ------------------------- ---------------------
N/A
----------------- -------------- --------------------------------- ------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- -------------- --------------- ---------------- ------------------------- -----------------------
N/A Nominal Delta
--------------- -------------- --------------- ---------------- ------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
---------------------------------------------------- ----------------------------------------------------------------
13,157,666 5.004%
---------------------------------------------------- ----------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
----------------------------------------------------------------------------
The Bank of New York Mellon Corporation is making this
disclosure as the ultimate parent company of: The Bank
of New York Mellon; The Dreyfus Corporation; The Boston
Company Asset Management LLC; BNY Mellon, National Association
and Pershing LLC.
Proxy Voting:
----------------------------------------------------------------------------
10. Name of the proxy holder: N/A
------------------------------------------------------------ --------------
11. Number of voting rights proxy N/A
holder will cease
to hold:
------------------------------------------------------------ --------------
12. Date on which proxy holder will N/A
cease to hold
voting rights:
------------------------------------------------------------ --------------
13. Additional information: N/A
------------------------------------------------------------ --------------
14. Contact name: Andrew Weiser
------------------------------------------------------------ --------------
15. Contact telephone number: 516-338-3752
------------------------------------------------------------ --------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAFKPAFAKEFF
(END) Dow Jones Newswires
June 28, 2016 07:14 ET (11:14 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about GW Pharm. (London Stock Exchange): 0 recent articles
More GW Pharm. News Articles